Build engaged audiences through publishing by curation.
Sign up with Facebook
Sign up with Twitter
I don't have a Facebook or a Twitter account
Start a free trial of Scoop.it Business
Glioblastoma multiforme (GBM) is a fast-growing, malignant brain tumor that occurred in 15 percent of the estimated 22,000 Americans diagnosed with brain and nervous system tumors in 2010. Although it responds to initial ...
Are you sure you want to delete this scoop?
Living Much Longer With Brain CancerdailyRxCancer cells are really smart. They can hide out during treatment. Or they can resist treatment only to appear later. They can also avoid the body's defense system.
Celgene's Abraxane improved pancreatic cancer survival in trialReutersPatients with advanced forms of pancreatic cancer, such as those tested in the Celgene trial, typically live 5.6 to 6.8 months following diagnosis, according to Dr.
Researchers have identified metabolic signatures that may pave the way for personalized therapy in glioma, a type of tumor that starts in the brain.
An ultrasound device for breast cancer screening -- the somo-v ABUS -- has been approved for use in women with dense breasts, the FDA announced Tuesday.
A completely new way of delivering anti-cancer drugs to tumors, using “minicells” derived from bacteria, has been tested for the first time in humans and found to be safe, well-tolerated and even induced stable disease in patients with advanced,...
A single case study has shown that vemurafenib (Zelboraf, Genentech) may be effective in treating patients with hairy cell leukemia (HCL). The drug jettisoned a chemotherapy-refractory patient with HCL into remission, according to researchers who reported the success story at the annual meeting of the American Society of Clinical Oncology (abstract 6519).
Cleveland Clinic Research, Dr. VInce Tuohy has developed a breast cancer vaccine that has proven 100 percent effective in three animal models. Needs 6 million dollars to test on women.
The combination of a selective aromatase inhibitor (AI) and estradiol analogue appears to be superior to an inhibitor alone as a first-line strategy to fight hormone receptor (HR)-positive metastatic breast cancer.
Older men had a small but significantly lower risk of cancer when they took a multivitamin on a daily basis, a new analysis of a large cohort study showed. Overall, men who took a daily multivitamin supplement had an 8% lower risk of cancer than men who were randomized to receive a placebo. Additionally, cancer mortality was 12% lower in the multivitamin arm, although the difference did not achieve statistical significance.
Primary source: Journal of the American Medical AssociationSource reference:Gaziano JM, et al "Multivitamins in the prevention of cancer in men. The Physicians Health Study II randomized controlled trial" JAMA 2012;doi:10.1001/jama.2012.14641.
Analysis of gene-expression profiles has led to identification of four distinct breast cancer subtypes, each of which has numerous subtype-specific and novel mutations, data from an NCI-sponsored research program showed.
The profiles subdivided breast cancer into luminal A, luminal B, HER2, and basal-like subtypes. The analysis identified almost all genes previously implicated in breast cancer but also revealed a number of novel genes not previously recognized as playing a role in breast cancer etiology.
The findings provide a basis for moving forward with research into the origin and treatment of breast cancer, according to a report published online in Nature.
Regorafenib (Stivarga), an inhibitor of multiple kinase enzymes, has been approved for use in treatment-refractory, metastatic colorectal cancer, the FDA announced Thursday.
Approval was based primarily on the 760-patient CORRECT trial, in which patients treated with regorafenib had a median overall survival of 6.4 months compared with 5 months in a placebo group (P=0.005). Patients in the study had metastatic colorectal cancer that was progressing after treatment with approved standard therapies. All patients received best supportive care in addition to regorafenib or placebo.
The drug improved progression-free survival only slightly in the trial -- the median was 2 months in treated patients versus 1.7 months with placebo.
Adverse effects developing during the study and attributable to the drug included fatigue, hand-foot skin reactions, diarrhea, anorexia, voice changes, hypertension, mucositis, and rash -- all occurring in at least 25% of patients receiving regorafenib.
The show profiled the biotech company's brain tumour vaccine ICT-107, which is in Phase 2b clinical trials to treat patients with glioblastoma multiforme, an aggressive brain cancer. ImmunoCellular's Phase 2 trial is a double-blind and ...
Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial ...Sacramento BeeThe Company's lead program is a 300-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM).
ABC15.com (KNXV-TV)Pregnancy tests are said to detect some types of testicular cancer in menABC15.com (KNXV-TV)If you've been near social media or on the Internet, you may be aware of the buzz over posts claiming a teenage boy took a home pregnancy...
Johnson & Johnson says that an application to get expanded approval for its prostate cancer drug Zytiga has been given a priority review by regulates in the USA.
German drugmaker Bayer has failed in the first stage of its bid to stop Indian group Natco from selling a rock-bottom-priced version of its liver and kidney cancer drug Nexavar in India.
SAN FRANCISCO -- A tamoxifen-like drug slowed progression of advanced breast cancer previously treated with a nonsteroidal aromatase inhibitor, results of a small Japanese trial suggested.
The European Commission has granted Takeda's Adcetris (brentuximab vedotin) a conditional marketing approval for the treatment of certain lymphomas.
Using advanced microscopes equipped with tissue-penetrating laser light, cancer imaging experts at Johns Hopkins have developed a promising, new way to accurately analyze the distinctive patterns of ultra-thin collagen fibers in breast tumor tissue samples and to help tell if the cancer has spread.
The Johns Hopkins researchers say their crisscrossing optical images, made by shining a laser back and forth across a biopsied tissue sample a few millionths of a meter thick, can potentially be used with other tests to more accurately determine the need for lymph node biopsy and removal in women at risk of metastatic breast cancer.
For additional information, go to:http://icmic.rad.jhmi.edu/ICMICorganization/ProgDirZB.htmlhttp://projectreporter.nih.gov/reporter_searchresults.cfm
Approved under accelerated approval - Synribo (omacetaxine mepesuccinate) for use in patients whose cancer progressed after treatment with at least two tyrosine kinase inhibitors, also used for CML.
Survival rates are similar whether transplanted stem cells are from peripheral blood or bone marrow, although each has unique benefits, researchers found. But peripheral blood stem cells appeared to reduce the risk of graft failure, while a bone marrow transplant lowered the risk of chronic graft-versus-host disease (GVHD).
Primary source: New England Journal of MedicineAnasetti C, et al "Peripheral-blood stem cells versus bone marrow from unrelated donors" N Engl J Med 2012; 367(16): 1487-1496.
Context/Objectives: Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC).
Biomarkers predicting metastatic capacity might assist the development of better therapeutic strategies for aggressive cancers such as lung cancer. A new study showed that adenylate kinase-4 (AK4) is a progression-associated gene in human lung cancer that promotes metastasis. AK4 is upregulated in lung adenocarcinoma compared with normal cells. High AK4 expression was associated with advanced stage, disease recurrence and poor prognosis.